The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Predicted biological activity of intravitreal VEGF Trap
Abstract
AIM: To compare the intravitreal binding activity of VEGF Trap with that of ranibizumab against vascular endothelial growth factor (VEGF) using a time-dependent and dose-dependent mathematical model. METHODS: Intravitreal half-lives and relative equimolar VEGF-binding activities of VEGF Trap and ranibizumab were incorporated into a first-order decay model. Time-dependent VEGF Trap activities (relative to ranibizumab) for different initial doses (0.5, 1.15, 2 and 4 mg) were calculated and plotted. RESULTS: Seventy-nine days after a single VEGF Trap (1.15 mg) injection, the intravitreal VEGF-binding activity would be comparable to ranibizumab at 30 days. After injection of 0.5, 2 and 4 mg VEGF Trap, the intravitreal VEGF-binding activities (comparable to ranibizumab at 30 days) would occur at 73, 83 and 87 days, respectively CONCLUSION: On the basis of this mathematical model, VEGF Trap maintains significant intravitreal VEGF-binding activity for 10-12 weeks after a single injection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904
Self-citationPharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683
Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration
Gaudreault, J., Fei, D., Rusit, J., Suboc, P., & Shiu, V. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0601 · Cited by 501
Mordenti, J., Cuthbertson, R. A., Ferrara, N., Thomsen, K., Berleau, L., Licko, V., Allen, P. C., Valverde, C. R., Meng, Y. G., Fei, D. T. W., et al. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700507 · Cited by 350
Saishin, Y., Saishin, Y., Takahashi, K., Silva, R. L. E., Hylton, D., Rudge, J. S., Wiegand, S. J., & Campochiaro, P. A. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10246 · Cited by 239
NGUYEN, Q., SHAH, S., Hafiz, G., Quinlan, E., SUNG, J., CHU, K., Cedarbaum, J. M., & Campochiaro, P. A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.055 · Cited by 157
PREDICTED BIOLOGIC ACTIVITY OF INTRAVITREAL BEVACIZUMAB
Stewart, M. W. (2007) · Retina · doi:10.1097/iae.0b013e318158ea28 · Cited by 66
Self-citation
Cited by
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Papadopoulos, N., Martin, J., Ruan, Q., Rafique, A., Rosconi, M. P., Shi, E., Pyles, E. A., Yancopoulos, G. D., Stahl, N., & Wiegand, S. J. (2012) · Angiogenesis · doi:10.1007/s10456-011-9249-6 · Cited by 1,037
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion
Campochiaro, P. A., Clark, W. L., Boyer, D. S., Heier, J. S., Brown, D. M., Vitti, R., Kazmi, H., Berliner, A. J., Erickson, K., Chu, K. W., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.031 · Cited by 385
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Brown, D. M., Vitti, R., Berliner, A. J., Gao, B., Zeitz, O., Ruckert, R., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.010 · Cited by 385
Corneal Neovascularization: An Anti-VEGF Therapy Review
Chang, J.-H., Garg, N. K., Lunde, E., Han, K.-Y., Jain, S., & Azar, D. T. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.007 · Cited by 381
Brown, D. M., Heier, J. S., Clark, W. L., Boyer, D. S., Vitti, R., Berliner, A. J., Zeitz, O., Sandbrink, R., Zhu, X., & Haller, J. A. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.09.026 · Cited by 365
Avery, R. L., Castellarin, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R., Couvillion, S., Nasir, M. A., Rabena, M. D., Maia, M., et al. (2017) · Retina · doi:10.1097/iae.0000000000001493 · Cited by 352
Sun, X., Yang, S., & Zhao, J. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97653 · Cited by 347
Boyer, D., Heier, J., Brown, D. M., Clark, W. L., Vitti, R., Berliner, A. J., Groetzbach, G., Zeitz, O., Sandbrink, R., Zhu, X., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.01.042 · Cited by 258
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
Bakall, B., Folk, J. C., Boldt, H. C., Sohn, E. H., Stone, E. M., Russell, S. R., & Mahajan, V. B. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.02.017 · Cited by 229
Stewart, M. W., Rosenfeld, P. J., Penha, F. M., Wang, F., Yehoshua, Z., Bueno-Lopez, E., & Lopez, P. F. (2011) · Retina · doi:10.1097/iae.0b013e31822c290f · Cited by 225
Self-citationAflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
Cho, H., Shah, C. P., Weber, M., & Heier, J. S. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303344 · Cited by 161
Aflibercept for neovascular age-related macular degeneration
Sarwar, S., Clearfield, E., Soliman, M. K., Sadiq, M. A., Baldwin, A. J., Hanout, M., Agarwal, A., Sepah, Y. J., Do, D. V., & Nguyen, Q. D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011346.pub2 · Cited by 142
Fauser, S., Schwabecker, V., & Muether, P. S. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.05.025 · Cited by 85
Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Kiss, S., Grishanin, R., Nguyen, A., Rosario, R., Greengard, J. S., Nieves, J., Gelfman, C. M., & Gasmi, M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.007 · Cited by 29
“PK profile of aflibercept following IVT-injected aflibercept recombinant protein evaluated in this study was similar to the published clearance rates of aflibercept after IVT administration in rabbits and cynomolgus monkeys,(38,39) and the half-life in vitreous humor (106 h) was very close to human vitreous humor rate…”
Result
Metadata
- Authors
- Stewart, M. W., & Rosenfeld, P. J.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2008-03-20
- Volume
- 92
- Issue
- 5
- Pages
- 667-668
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2143874967
- Cited by
- 375
- References
- 9
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.